Repair, Immunity & Cellular Peptides
A thymus-derived peptide studied as an immune modulator. Status: Approved in some countries for chronic hepatitis B and C; not FDA-approved in the U.S.
-
Thymosin alpha 1 (Tα1) is 28 amino acid peptide derived from the thymus gland. A peptide derived from the thymus gland, studied as an immune modulator. Approved for clinical use in some countries for chronic hepatitis B and C; not FDA-approved in the United States."
-
Tα1 has been shown to enhance the innate immune response to viral infections by promoting the activity of natural killer (NK) cells and cytotoxic T lymphocytes. Studies have shown its efficacy in reducing viral loads in patients with hepatitis B and C, as well as in viral respiratory infections such as influenza and COVID-19. Mechanistically, Tα1 upregulates interferon-alpha (IFN-α) and other cytokines critical for antiviral defense.
A clinical trial demonstrated the efficacy of Tα1 in reducing HBV DNA levels in chronic hepatitis B patients (ClinicalTrials.gov Identifier: NCT00006292).
Its role as a potential adjunctive therapy in COVID-19 was noted in studies emphasizing Tα1’s ability to modulate cytokine storms and prevent severe complications.
-
Tα1 has been shown to boosts the phagocytic activity of macrophages and enhances the maturation of dendritic cells, improving bacterial and fungal clearance. It has shown promise in treating infections caused by multidrug-resistant organisms, and its adjuvant use has been investigated for opportunistic infections in immunosuppressed patients.
Animal studies demonstrated that Tα1 reduces bacterial burden in sepsis models by enhancing macrophage activation.
In vitro research highlights its effectiveness against Candida albicans through immune system modulation.
-
Tα1 exhibits antitumor effects by restoring immune surveillance mechanisms often impaired in cancer. It has been shown to promotes T-cell proliferation and activation while increasing the presentation of tumor antigens through dendritic cells. Tα1 is particularly effective in combination with chemotherapy or immune checkpoint inhibitors, where it enhances therapeutic efficacy.
A study in non-small cell lung cancer patients revealed improved survival rates when Tα1 was combined with chemotherapy (doi:10.1007/s00432-020-03422-5).
Research on melanoma suggests that Tα1 aids in tumor regression by enhancing cytotoxic T-cell responses.
-
Tα1 plays a dual role in immune regulation by stimulating adaptive and innate immunity while reducing excessive inflammation. It has been shown to restore immune homeostasis in conditions of immune suppression or dysregulation, such as autoimmune
diseases or after chemotherapy. Mechanistically, Tα1 acts through toll-like receptor (TLR) pathways and nuclear factor kappa B (NF-κB), leading to balanced cytokine production.
Activation of TLR-9 and downstream signaling pathways enhances immune responses.
Regulation of NF-κB prevents hyperinflammatory states.
-
This page is for education and does not provide medical advice, diagnosis, treatment, or a recommendation to buy or use any product. The compound described may not be approved by the FDA for human use. Approval status and regulations change; information is current as of this page's last update. Time Kapsule provides only supervised, FDA-approved protocols and does not sell, supply, or endorse research-use-only peptides. Consult a licensed clinician before considering any therapy.